nordsci bpc 157 nord sci BPC-157: The Secret Weapon for Injury Repair & Gut Health BPC-157 → Newbridge Peptides

Huttenlocher PR, De Courten C, Garey LJ, Van, der Loos H

Giles GI, Nasim MJ, Ali W, Jacob C

Researchers use it in laboratory studies of fat metabolism under controlled conditions

Doses used in ARA-290 human trials Study context Sarcoidosis pilot (2012) Dose & route 2 mg IV Schedule 3x/week, 4 weeks Study context Sarcoidosis SFN (2013) Dose & route Daily subQ Schedule 28 days Study context Type 2 diabetes neuropathy (2014) Dose & route 4 mg subQ Schedule Daily, 28 days Study context Phase 2b sarcoidosis (2017) Dose & route 1, 4, or 8 mg subQ Schedule Daily, 28 days Study context Diabetic macular edema (2020) Dose & route 4 mg subQ Schedule Daily, 12 weeks This is trial reporting, not a dosing recommendation

The answer is I think so